ClinicalTrials.gg
CompletedNCT05242133Updated Oct 18, 2022

Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis

A Phase 3 interventional study of Pegylated interferon beta-1a and Interferon Beta-1A Prefilled Syringe in Relapsing Remitting Multiple Sclerosis (RRMS), sponsored by Cinnagen. Completed at 1 site in Iran, Islamic Republic of. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2022-10-18.

Sponsored by Cinnagen · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years after the study started (first participant enrolled Dec 2017, registered Jan 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
168
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, none under way, none of them phase 3. Interferon beta-1a · Multiple Sclerosis, Relapsing-Remitting.

Enrollment
10th of 21
168 · median 80
Started
2017
with 1 other
Phase 3
3 of 21
none open now
Registered
21st of 21
by date
Lead sponsor
1 of 21
Cinnagen

Among the 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting, this one is the 10th largest by enrollment, is one of 2 that started in 2017, is one of 3 in phase 3, and was the 21st registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

None of the 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →

About Interferon beta-1a

Interferon beta-1a: first FDA approval 1996 (AVONEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of peginterferon beta-1a produced by CinnaGen compared with CinnoVex® (CinnaGen) in subjects with relapsing remitting multiple sclerosis (RRMS). All the participants will receive one of the following regimens: pegylated interferon beta-1a (CinnaGen), autoinjector (Physioject™), 125mcg, subcutaneous, every 2 weeks for 24 months or CinnoVex® (CinnaGen), prefilled syringes, 30mcg, intramuscular, once a week for 24 months. The primary objective of this study is to verify the non-inferiority of peginterferon beta-1a (CinnaGen) versus CinnoVex® (CinnaGen) in reducing the annualized relapse rate (ARR) in participants with relapsing remitting multiple sclerosis (RRMS) at 2 years.

The secondary objectives of this study are:

  • Reducing the total number of new or newly enlarging T2 hyperintense lesions on brain magnetic resonance imaging (MRI) scans
  • Slowing the progression of disability
  • Comparing adverse events
Read the detailed description

The purpose of this phase III, randomized, active control, parallel, non-inferiority, multicenter study is to verify the non-inferiority of peginterferon beta-1a produced by CinnaGen versus CinnoVex® (CinnaGen) in subjects with relapsing remitting multiple sclerosis (RRMS).

All the participants will receive one of the following regimens:

I. Pegylated interferon beta-1a (CinnaGen), autoinjector (Physioject™), 125mcg, subcutaneous, every 2 weeks for 24 months; II. Interferon beta-1a, CinnoVex® (CinnaGen), prefilled syringes, 30mcg, intramuscular, once a week for 24 months.

With the aim of ensuring the compliance and safety, in the first two months of the study, in each monthly visit, a trained expert nurse will be responsible for drug injection for both intervention groups and will train all patients for self-injection. By the end of the first two months to the end of the study, patients will self-inject the medication in both groups.

All other cares or medications will be allowed to continue by patients, except for disease modifying therapies (DMTs) and medicines which affect the immune system (e.g. immunosuppressants and immunomodulators). Any concomitant medication will be recorded for patients in their regular visits.

The primary objective of this study is to verify the non-inferiority of peginterferon beta-1a (CinnaGen) versus CinnoVex® (CinnaGen) in reducing the annualized relapse rate (ARR) in participants with relapsing remitting multiple sclerosis (RRMS) at 2 years.

The secondary objectives of this study are:

  • Reducing the total number of new or newly enlarging T2 hyperintense lesions on brain magnetic resonance imaging (MRI) scans
  • Slowing the progression of disability
  • Comparing safety issues

Sample size:

Group sample sizes of 76 in the experimental group and 76 in the active comparator group will achieve almost 80% power to detect non-inferiority using a one-sided, two-sample t-test. The margin of non-inferiority is 0.17. The true ratio of the means at which the power is evaluated is 1.00. The significance level of the test is 0.05. The coefficients of variation of both groups are assumed to be 0.4. The dropout rate is assumed to be 10%; hence 168 patients will be randomized.

Sequence generation:

The randomization plan of the patients will be carried out centrally using Cran-R version 3.2.3. Using permuted block randomization, blocks (length of each block is 4 or 2) will be made, for a total of 168 patients with 1:1 allocation ratio. Once the randomization has been made, each patient is given a code with which he/she will be identified throughout the study. The assigned code will be made up of 3 numbers (corresponding to the randomization number) and by 4 initials (corresponding to the 2 first letter of the first name, the 2 first letter of the first surname) and 2 numbers (center code). The randomization number will be assigned in a consecutive way.

Blinding:

Because of the different routes of administration of drugs in the study groups, patient blinding is not possible.

Data management:

Principal investigator is responsible for safe keeping of all patients' records at all times. Original hard copies of case report forms (CRFs) will be sent to Clinical Trial Consultants (CTCs) upon request and at the end of the study for data management. A copy of the records will be kept at the center. Sending and receiving of all patients' documents will be made after taking into consideration safety and security issues.

Principal investigator should set necessary schemes to control the quality of:

  • Drug delivery, storage and handling
  • All clinical examinations
  • Laboratory tests and other paraclinical investigations
  • Patient care

Data monitoring:

The objectives of the data quality control (QC) are:

  • To ensure the existence of the patients and the respect of ethics, including signed patient informed consent forms (ICFs)
  • To identify the issues, including systematic issues, as early as possible for appropriate setting of action plans and corrective actions
  • To ensure the validity of the data To meet these objectives, the possibility of the sites' QC must be explained to the investigators at the time of the study initiation and agreed by them. QC will be performed on sites by the Local Study Teams.

QC will be started after inclusion of 30% of patients and will be ended before 80% of inclusion.

Two levels of QC will be performed:

Quality of CRF completion: At the time of CRF reception, the Local Study Team will review the completed CRFs in order to assess the completeness and the quality of completion. The Local Study Team (monitor or designee) is responsible to set up an action plan in order to improve the quality at site level. In case of systematic issue, the Local Study Team will inform the Corporate Study Team.

Central database checks: In addition to the standard data management activities, the following parameters will be systematically assessed as a part of the QC of the study, in country- and site-levels by the Study Central Team:

  • Signed ICFs
  • Rates of error and missing data for the key variables
  • Completion of the patients' questionnaire
  • Enough clarity of the forms During the QC visit, the monitor will have to complete a QC visit report.

Principal investigators should set necessary schemes to control the quality of:

  • Signed ICF
  • Drug delivery, storage and handling
  • All clinical examinations
  • Laboratory tests and other paraclinical investigations
  • Patient care

Research ethics approval:

  • Ethics committee approval is mandatory for this study to commence.
  • No patient will be recruited to this study without an informed consent.
  • It will be made clear to all patients that they can leave the study any time they desire with no need for any explanation.
  • To keep confidentiality in case of a lost document, the name and surname of the patients will not appear on evaluation forms.
  • Adverse effect report forms will be processed after each visit. Research team is responsible for dealing with immediate aftermath of any adverse event regardless of whether or not the event is directly related to the medication that is being studied.
  • All serious adverse events should be reported to DSMB (Data and Safety Monitoring Board). The board is responsible for making necessary decisions to deal with the situation. These decisions may include determining the relationship between the drug and the observed adverse event.
  • The protocol, CRF, information for patients and informed consent forms will be submitted to the ethics committees responsible for the investigators in TUMS, for review and approval according to the national regulatory guidelines.
03

Conditions studied

  • Relapsing Remitting Multiple Sclerosis (RRMS)
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Relapsing-remitting multiple sclerosis diagnosis (based on McDonald criteria 2010)
  • Expanded Disability Status Scale between 0 to 5
  • At least one relapse having occurred within the past 12 months.
  • Subjects have refused alternative treatments and other available therapies
  • Ability to understand the purpose and risks of the study and provide signed and dated
  • Negative pregnancy test for women of childbearing age

Exclusion criteria

Exclusion Criteria:

  • Primary progressive, secondary progressive, or progressive relapsing MS
  • Female subjects considering becoming pregnant while in the study or currently breastfeeding
  • Subjects for whom MRI was , i.e., who had pacemakers or other contraindicated implanted metal devices, were allergic to gadolinium, or had claustrophobia that could not be medically managed.
  • Unwillingness or inability to comply with the requirements of the protocol including the presence of any condition (physical, mental or social) that was likely to affect the subject's ability to comply with the protocol.
  • Pre-specified laboratory abnormalities
  • History of any (as determined by the Investigator) cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, and renal, or other major disease that would preclude participation in a clinical trial.
  • History of malignant disease, including solid tumors and hematologic (with the exception of basal cell and squamous cell carcinomas of the skin that have been completely excised and are considered cured).
  • History of seizure disorder or unexplained blackouts or history of a seizure within 3 months prior to baseline.
  • History of suicidal ideation within 3 months prior to Baseline or an episode of severe depression within 3 months prior to Baseline. Severe depression is defined as an episode of depression that requires hospitalization, or at the discretion of the Investigator.
  • Abnormal screening blood tests exceeding any of the limits defined below:

    • /serum glutamate pyruvate transaminase (ALT/SGPT) greater than 2 times the (>2 × ULN) or aspartate transaminase/serum glutamic oxaloacetic transaminase (AST/SGOT) >2 × ULN or >1.5 × ULN.
    • Total white blood cell count (WBC) \<4000 /mm3
    • (ANC) of \< 1500 /mm3
    • count \<150,000 c/mm3
    • \<10 g/dL in female subjects; \<11 g/dL in male subjects
    • Serum creatinine> upper limit of normal lab value
  • A MS relapse that has occurred within the 30 days prior to randomization and/or the subject has not been stabilized from a previous relapse prior to randomization (Day 1).
  • Elective surgery performed within 2 weeks prior to randomization (Day 1) or scheduled to be performed through the study interval.
  • Treatment with other agents to treat MS symptoms or underlying disease as specified below:
  • Agent Time Required off Agent Prior to Baseline:

    • Any prior treatment with:

      • Total Lymphoid Irradiation
      • Cladribine
      • T-cell Vaccine
      • Natalizumab
      • Rituximab
      • Plegridy®
    • Prior treatment within 1 year of randomization:

      • Cyclophosphamide
      • Mitoxantrone
    • Prior treatment within 6 months prior to randomization:

      • Cyclosporine
      • Plasma exchange
      • Intravenous immunoglobulin (IVIG)
      • Azathioprine
      • Methotrexate
    • Subjects must have discontinued interferon treatment at least 6 months prior to randomization
    • Prior treatment within 30 days prior to randomization:

      • Systemic
    • Prior treatment with glatiramer acetate within 4 weeks prior to randomization
    • Treatment with another drug or approved therapy for investigational use within the 6 months prior to randomization
    • Other unspecified reasons that, in the opinion of the Investigator, made the subject unsuitable for enrolment
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
168 participants (actual)

Study arms

  • Experimental
    CinnaGen peginterferon beta-1a

    Pegylated interferon beta-1a (CinnaGen) autoinjector (Physioject™),125 mcg, subcutaneous (SC) injection, every 2 weeks, for 24 months

    Drug: Pegylated interferon beta-1a

  • Active comparator
    CinnoVex®

    Interferon Beta-1A Prefilled Syringe, CinnoVex® (CinnaGen), 30 mcg, intramuscular injection, once a week, for 24 months

    Drug: Interferon Beta-1A Prefilled Syringe

Interventions

  • Pegylated interferon beta-1a (CinnaGen) autoinjector (Physioject™),125 mcg, subcutaneous (SC) injection, every 2 weeks, for 24 months

  • Interferon Beta-1A Prefilled Syringe, CinnoVex® (CinnaGen), 30 mcg, intramuscular injection, once a week, for 24 months

    Also known as: CinnoVex®

06

What researchers measure

Primary outcomes

  1. Annualized Relapse Rate

    The total number of relapses divided by the total person-time at risk of relapse. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection.

    Time frame: 96 weeks

Secondary outcomes

  1. Proportion of patients with 12 weeks of sustained disability progression

    Clinical evaluation

    Time frame: Baseline up to week 96

  2. Total number of new or newly enlarging T2-hyperintense lesions as detected by brain MRI

    Sum of the individual number of new or newly enlarging T2-hyperintense lesions at weeks 24, 48, and 96

    Time frame: Baseline up to week 96

  3. Total number of gadolinium enhancing lesions as detected by brain MRI

    Sum of the individual number of gadolinium enhancing lesions at weeks 24, 48, and 96

    Time frame: Baseline up to week 96

  4. Total number of new or newly enlarging T1 hypointense lesions as detected by brain MRI

    Sum of the individual number new T1 hypointense lesions at weeks 24, 48, and 96

    Time frame: Baseline up to week 96

  5. Total number of new active lesions as detected by brain MRI

    Sum of gadolinium enhancing plus non-enhancing new or newly enlarging T2 hyperintense lesions

    Time frame: Baseline up to week 96

  6. Volume of new or newly enlarging T2 hyperintense lesions as detected by brain MRI

    Inflammatory activity based on MRI measurement of new or newly enlarging T2 lesion volume

    Time frame: Baseline up to week 96

  7. Volume of gadolinium enhancing lesions as detected by brain MRI

    Inflammatory activity based on MRI measurement of gadolinium enhancing T1 lesion volume

    Time frame: Baseline up to week 96

  8. Volume of new or newly enlarging T1 hypointense lesions as detected by brain MRI

    Inflammatory activity based on MRI measurement of hypointense T1 lesion volume

    Time frame: Baseline up to week 96

  9. Brain atrophy

    Percentage of brain volume change from baseline detected by brain MRI

    Time frame: Baseline up to week 96

Other outcomes

  1. Number of participants with Adverse Events (AEs)

    Intensity, seriousness and causality assessment of observed AEs, and abnormal laboratory findings

    Time frame: 96 weeks

07

Study locations

1 site
  • Sina Hospital
    Tehran, Iran, Islamic Republic of
08

References and documents

Publications

  • Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S, Deykin A; ADVANCE Study Investigators. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014 Jul;13(7):657-65. doi: 10.1016/S1474-4422(14)70068-7. Epub 2014 Apr 30. PubMed 24794721 ↗
  • National Multiple Sclerosis Society. (2017). FDA Approves Plegridy (Pegylated Interferon Beta) For Relapsing MS. [online] Available at: http://www.nationalmssociety.org/About-the-Society/News/FDA-Approves-Plegridy-Pegylated-Interferon-Beta [Accessed 2 Sep. 2017].
  • Anon, (2017). [online] Available at: http://www.cinnagen.com/index.php/our-products/human-medicines/cinnovex [Accessed 2 Sep. 2017].
  • Anon, (2017). [online] Available at: National Multiple Sclerosis Society. (2017). FDA Approves Plegridy (Pegylated Interferon Beta) For Relapsing MS. [online] Available at: http://www.nationalmssociety.org/About-the-Society/News/FDA-Approves-Plegridy-Pegylated-Interferon-Beta. [Accessed 2 Sep. 2017].
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Apr 2022, 52 months.

Of 28 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 65. This study's 52 months is above that.

Counting every sponsor, half of 38 studies reached it within 48 months; a quarter within 27 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2022
First posted
Feb 16, 2022
StartActual
Dec 20, 2017
Primary completionActual
Apr 27, 2022
CompletionActual
Apr 27, 2022
Last update
Oct 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05242133
Lead sponsor
Cinnagen
Responsible party
Sponsor
First posted
Feb 16, 2022
Start date
Dec 20, 2017
Primary completion
Apr 27, 2022
Completion
Apr 27, 2022
Last update
Oct 18, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Interferon beta-1a

Start the discussion